Our Clinical Trials
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Please visit OPERA01study.com for more information about participation in the trial.
Palazestrant in Combination with Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02)
Please visit OPERA01study.com for more information about participation in the trial.
Phase 1b Study of OP-1250 (Palazestrant) in Combination with Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Please visit OPERA01study.com for more information about participation in the trial.
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Please visit OPERA01study.com for more information about participation in the trial.